一个计算医学框架,整合了多omics,系统生物学和人工神经网络,用于阿尔茨海默病的治疗发现
Yisheng Yang1, Yizhu Diao1, Lulu Jiang2
1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Acta pharmaceutica Sinica. B
|October 6, 2025
概括
一个新的计算框架PI4AD通过整合多omics数据和人工神经网络来帮助阿尔茨海默病 (AD) 的治疗发现. 它优先考虑临床目标,并确定新的途径,提供超越粉样蛋白/蛋白的新策略.
科学领域:
- 计算生物学是一种计算生物学.
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
背景情况:
- 将遗传发现转化为阿尔茨海默病 (AD) 的治疗方法仍然是一个重大挑战.
- 现有的方法往往只集中在粉样蛋白和蛋白通路上.
研究的目的:
- 引入PI4AD,一个用于AD治疗发现的计算医学框架.
- 利用多学科数据,系统生物学和人工神经网络来确定目标优先级和途径分析.
- 通过分析路径交叉通话来确定AD特定的目标和治疗策略.
主要方法:
- 整合多学科数据,网络分析和人工神经网络.
- 开发一个自我组织的优先级地图,以区分AD特定的目标.
- 途径交叉分析以识别节点基因和药物重定向候选人.
主要成果:
- PI4AD成功地确定了已知的治疗点,如APP和ESR1.
- 该框架确定了特定疾病的分子特征和关键节点基因 (例如HRAS,MAPK1).
- 路径交叉分析揭示了潜在的药物重定向候选人和相关网络模块.
结论:
- PI4AD提供了一个系统遗传学基础,用于AD的合理治疗开发.
- 该框架的重点是以Ras为中心的途径,为粉样蛋白/tau为中心的范式提供了一个补充策略.
- PI4AD有可能重新定义AD治疗策略,可能与mRNA疗法结合.
相关概念视频
01:22Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K